Clinical effect of propiverine in patients with urge or stress incontinence. Kobe University Incontinence Study Group
スポンサーリンク
概要
- 論文の詳細を見る
プロピベリン(20mg/日,28日間)の臨床効果を49名の患者を対象に多施設協同研究で調査した.排尿回数の中等度以上の改善を切迫性及び腹圧性尿失禁で52%及び54%の患者で達成出来た.尿意切迫感はそれぞれ91%及び58%の症例で改善した.尿失禁はそれぞれ97%及び71%の症例で改善した.日常生活の制限はそれぞれ94%及び64%の症例で改善が見られた.軽度の副作用を5名に,臨床検査値の変動を2名に認めたThe efficacy and tolerability of propiverine hydrochloride (20 mg/day) were evaluated in the treatment of a total of 49 Japanese patients (35 with urge incontinence and 14 with stress incontinence) in an open multicenter trial lasting 28 days. The effects on the frequency of urination, urinary incontinence, urinary urgency, and daily living activities were evaluated through the voiding diaries filled out by the patients. Moderate or greater degree of improvement was attained in micturition frequency by 52 and 54% of the patients with urge incontinence and with stress incontinence, respectively, in urinary urgency by 91 and 58%, in urinary incontinence by 97 and 71%, and in daily living activities by 94 and 64%. Although minor adverse reactions (5 patients) and abnormal values in blood chemistry (2 patients) were recorded in 7 patients, all of these patients completed the trial. These results suggest that propiverine hydrochloride is a safe and effective drug of choice for the treatment of not only urge incontinence but also stress incontinence in patients diagnosed in a clinical setting.
論文 | ランダム
- 491 回転炉床式加熱炉のシミュレーションモデルの開発(加熱炉・焼鈍設備, 加工, 日本鉄鋼協会 第 105 回(春季)講演大会)
- 168 ミスト冷却の熱伝運特性と連鋳鋳片の抜熱挙動 : 連鋳用ミスト冷却技術の開発第 1 報(連鋳表面疵・内部割れ, 製鋼, 日本鉄鋼協会 第 105 回(春季)講演大会)
- 膀胱腫瘍を合併した腎不全愚者の透析経験 : 第239回北海道地方会
- 種々なtroubleを伴なつた人工透析患者の2例 : 第225回北海道地方会
- 1)チスチン尿症の1例,2)子宮癌の骨盤内浸潤による無尿患者の透析経験 : 第222回北海道地方会